A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer
出版年份 2019 全文链接
标题
A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer
作者
关键词
-
出版物
Frontiers in Oncology
Volume 9, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2019-10-25
DOI
10.3389/fonc.2019.01066
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy
- (2019) David Zahavi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- T-cell Immunoglobulin and ITIM Domain Contributes to CD8+ T-cell Immunosenescence
- (2018) Yangzi Song et al. AGING CELL
- KLRG1 + Effector CD8 + T Cells Lose KLRG1, Differentiate into All Memory T Cell Lineages, and Convey Enhanced Protective Immunity
- (2018) Dietmar Herndler-Brandstetter et al. IMMUNITY
- A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
- (2018) Daniela S. Thommen et al. NATURE MEDICINE
- Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
- (2018) Shrujal Baxi et al. BMJ-British Medical Journal
- Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
- (2018) Shrujal Baxi et al. BMJ-British Medical Journal
- Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of Hepatocellular Carcinoma
- (2018) Hyung-Don Kim et al. GASTROENTEROLOGY
- Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression
- (2018) Colt A. Egelston et al. Nature Communications
- Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas
- (2017) Guoying Zhou et al. GASTROENTEROLOGY
- Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
- (2017) Elizabeth R Plimack et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Pembrolizumab in Non–Small-Cell Lung Cancer
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elevated regulatory T cells, surface and intracellular CTLA-4 expression and interleukin-17 in the lung cancer microenvironment in humans
- (2016) Iwona Kwiecien et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Early Effector T Lymphocytes Coexpress Multiple Inhibitory Receptors in Primary Non–Small Cell Lung Cancer
- (2016) Elena Tassi et al. CANCER RESEARCH
- A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells
- (2016) Meromit Singer et al. CELL
- Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis
- (2016) Andrea Schietinger et al. IMMUNITY
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
- (2016) Kei Muro et al. LANCET ONCOLOGY
- Erratum: Corrigendum: CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
- (2016) Yu-Hwa Huang et al. NATURE
- Into the Clinic With Nivolumab and Pembrolizumab
- (2016) Catherine A. Shu et al. ONCOLOGIST
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Expression of immune checkpoints in T cells of esophageal cancer patients
- (2016) Jinhua Xie et al. Oncotarget
- TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
- (2015) Joe-Marc Chauvin et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
- (2015) Lieping Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Combination cancer immunotherapy and new immunomodulatory targets
- (2015) Kathleen M. Mahoney et al. NATURE REVIEWS DRUG DISCOVERY
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overcoming T cell exhaustion in infection and cancer
- (2015) Kristen E. Pauken et al. TRENDS IN IMMUNOLOGY
- T-cell exhaustion in the tumor microenvironment
- (2015) Y Jiang et al. Cell Death & Disease
- TIMgenes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity
- (2015) Gordon J. Freeman et al. IMMUNOLOGICAL REVIEWS
- Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation
- (2014) Bertram Bengsch et al. JOURNAL OF HEPATOLOGY
- T-Cell Immunotherapy: Looking Forward
- (2014) Jacqueline Corrigan-Curay et al. MOLECULAR THERAPY
- CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
- (2014) Yu-Hwa Huang et al. NATURE
- The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions
- (2014) Christopher J Chan et al. NATURE IMMUNOLOGY
- Expanded CD8+ T cells of murine and human CLL are driven into a senescent KLRG1+ effector memory phenotype
- (2013) Joachim Rudolf Göthert et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
- (2013) Joel Crespo et al. CURRENT OPINION IN IMMUNOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
- (2012) P. A. Prieto et al. CLINICAL CANCER RESEARCH
- Different inhibitory capacities of human and mouse KLRG1 are linked to distinct disulfide-mediated oligomerizations
- (2012) Maike Hofmann et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Tumor immunity times out: TIM-3 and HMGB1
- (2012) Daolin Tang et al. NATURE IMMUNOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization
- (2012) Lukas Baitsch et al. PLoS One
- 2B4+ CD8+ T cells play an inhibitory role against constrained HIV epitopes
- (2011) Kim N. Aldy et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1
- (2011) J. Fourcade et al. CANCER RESEARCH
- Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
- (2011) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
- (2010) J.-J. Park et al. BLOOD
- The NK receptor KLRG1 is dispensable for virus-induced NK and CD8+ T-cell differentiation and function in vivo
- (2010) Carsten Gründemann et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- The molecular basis of the failed immune response in chronic HBV: Therapeutic implications
- (2010) Mala K. Maini et al. JOURNAL OF HEPATOLOGY
- T Cell/Transmembrane, Ig, and Mucin-3 Allelic Variants Differentially Recognize Phosphatidylserine and Mediate Phagocytosis of Apoptotic Cells
- (2010) Rosemarie H. DeKruyff et al. JOURNAL OF IMMUNOLOGY
- Coexpression of PD-1, 2B4, CD160 and KLRG1 on Exhausted HCV-Specific CD8+ T Cells Is Linked to Antigen Recognition and T Cell Differentiation
- (2010) Bertram Bengsch et al. PLoS Pathogens
- KLRG1—more than a marker for T cell senescence
- (2009) Sian M. Henson et al. AGE
- KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells
- (2009) S. M. Henson et al. BLOOD
- The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation
- (2009) Guifang Cai et al. IMMUNOLOGICAL REVIEWS
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
- (2009) Brian T Fife et al. NATURE IMMUNOLOGY
- Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection
- (2008) R. Brad Jones et al. JOURNAL OF EXPERIMENTAL MEDICINE
- CD160 and BTLA: LIGHTs out for CD4+ T cells
- (2008) Jonathan Kaye NATURE IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search